SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the clinical value of the PROSTest to detect biochemical recurrence in ...

SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the utility of the PROSTest to predict response to 177 Lu-PSMA therapy in ...

Dr. Abhilash Moolupuri presented the initial exploratory and phase I/II results of a trial evaluating a novel PSMA-targeting ...

Bicycle Therapeutics announced two poster presentations at the 2025 ASCO Annual Meeting, featuring preliminary results from the Phase 1/2 Duravelo-1 study evaluating the Nectin-4-targeting Bicycle® ...

Erectile Dysfunction - Read the latest Erectile Dysfunction research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

ASCO 2024 Kidney Cancer ASCO 2024: What Is Variant Histology Renal Cell Cancer and What Are the Available Treatment Options? ASCO 2024: Phase 1b/2 Study of Combination 177Lu Girentuximab plus ...

This study, presented at SNMMI 2025, aimed to further evaluate the safety profile and determine the optimal therapeutic dose of 177 Lu-P17-088, while also exploring its preliminary efficacy in the ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a kidney and bladder cancers poster session.

Bladder Cancer - Read the latest Bladder Cancer research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

Interdisciplinary Genitourinary Cancer Forum featured a metastatic urothelial carcinoma session and a presentation by Dr.

ASCO GU 2025 Kidney Cancer ASCO GU 2025: Case-Based Session: Failure of Immunotherapy in Renal Cell Cancer – What’s Next ASCO GU 2025: Adjuvant Therapy in Renal Cell Cancer: A Practical Guide ASCO GU ...

Neeraj Agarwal is joined by Wolfgang Fendler to discuss PSMA PET prognostication data. Dr. Fendler's international consortium of 50 sites analyzed 6,000 patients to develop risk stratification models ...